News
3d
Zacks.com on MSNHow Will Pfizer's Oncology Drugs Perform in Q2 Earnings?PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...
Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.
15don MSN
At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average dividend payer in the S&P 500. If it can't maintain its payout-raising streak, ...
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
Regeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...
Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...
A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines ...
A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines ...
The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is ...
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results